# US 2023/0324369 A1 · Cellular populations and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0324369 A1
- Document ID: US20230324369A1
- Status: Published application
- Kind: A1
- Application number: 18/298,129
- Filed: 2023-04-10
- Published: 2023-10-12
- Earliest claimed: 2017-04-07
- Assignees: The Council of the Queensland Institute of Medical Research
- Applicants: The Council of the Queensland Institute of Medical Research
- Inventors: Geoffrey R. Hill; Ping Zhang
- Web page: https://patentgrep.com/patent/US20230324369A1

## CPC

- G01N 33/505: {involving T-cells}
- A61K 40/10: characterised by the cell type used
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/22: Immunosuppressive or immunotolerising
- A61K 40/418: {Antigens related to induction of tolerance to non-self}
- C07K 14/535: Granulocyte CSF; Granulocyte-macrophage CSF
- C07K 14/5412: {IL-6}
- C07K 14/5428: {IL-10}
- C07K 14/5446: {IL-16}
- C07K 14/70514: {CD4}
- C12N 5/0637: {Immunosuppressive T lymphocytes, e.g. regulatory T cells or Treg}
- A61K 40/50: characterised by the use of allogeneic cells
- A61K 2239/38: characterised by the dose, timing or administration schedule
- C12N 2740/13043: viral genome or elements thereof as genetic vector
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Disclosed are methods of identifying immunosuppressive TR1 regulatory T cells, including methods of diagnosing the presence of immune tolerance, methods of producing immunosuppressive regulatory T cells, and methods of eliciting immune tolerance in a subject. These methods include screening T cells to detect Eomes+IL-10+ T cells or expressing recombinant Eomes in T cell populations to generate immunosuppressive regulatory T cells.

## Claims

### Claim at position 1

1-67. (canceled)

### Claim 68

A method of identifying immunosuppressive TR1 regulatory T cells in a sample, the method comprising: screening T cells in the sample for Eomes+IL−10+CD4+T cells, detecting Eomes+IL−10+CD4+T cells; and identifying the detected T-cells as immunosuppressive TR1 regulatory T cells.

### Claim 69 (depends on 68)

The method of claim 68, further comprising isolating the identified immunosuppressive regulatory T-cells.

### Claim 70 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomeshi CD4+T cells.

### Claim 71 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10hi CD4+T cells.

### Claim 72 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting EomeshiIL−10hi CD4+T cells.

### Claim 73 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting T-betloEomes+IL−10+CD4+T cells.

### Claim 74 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+T cells that are positive or high for IFN□.

### Claim 75 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+T cells that are positive for at least one of CD122, α4β7, LAG-3, Ly6C and TIGIT.

### Claim 76 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+T cells that are negative or low for one or more of CD25, CD69 and FoxP3.

### Claim 77 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+T cells that are positive for at least one of CD122, α4β7, LAG-3, Ly6C and TIGIT, and that are negative or low for one or more of CD25, CD69 and FoxP3.

### Claim 78 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+ T cells that are negative or low for at least one TH2 cytokine.

### Claim 79 (depends on 78)

The method of claim 78, wherein the at least one TH2 cytokine is selected from the group consisting of IL-4, IL-13 and IL-5.

### Claim 80 (depends on 68)

The method of claim 68, wherein the screening of the T cells in the sample comprises detecting Eomes+IL−10+CD4+T cells that are negative or low for at least one TH17 cytokine.

### Claim 81 (depends on 80)

The method of claim 80, wherein the at least one TH17 cytokine is selected from the group consisting of IL-17, IL-6 and GM-CSF.

### Claim 82 (depends on 68)

The method of claim 68, further comprising detecting suppression by the Eomes+IL−10+CD4+T cells of at least one immune function selected from the group consisting of IL-2 production, cell proliferation, cytokine production, cell migration, and effector functions, killing, and T-cell proliferation.

### Claim 83 (depends on 68)

The method of claim 68, wherein the sample is a peripheral blood mononuclear cell sample.

### Claim 84 (depends on 68)

The method of claim 68, wherein the sample is a lymphoid tissue sample.
